[go: up one dir, main page]

WO2007058991A3 - Mutations and polymorphisms of c-abl - Google Patents

Mutations and polymorphisms of c-abl Download PDF

Info

Publication number
WO2007058991A3
WO2007058991A3 PCT/US2006/043898 US2006043898W WO2007058991A3 WO 2007058991 A3 WO2007058991 A3 WO 2007058991A3 US 2006043898 W US2006043898 W US 2006043898W WO 2007058991 A3 WO2007058991 A3 WO 2007058991A3
Authority
WO
WIPO (PCT)
Prior art keywords
abl
mutations
polymorphisms
mutant
various aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/043898
Other languages
French (fr)
Other versions
WO2007058991A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007058991A2 publication Critical patent/WO2007058991A2/en
Publication of WO2007058991A3 publication Critical patent/WO2007058991A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the c ABL gene. The invention provides new c ABL mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the c ABL mutations of the invention, expression vectors encoding the c ABL mutant polypeptides of the invention and organisms that express the c ABL mutant and polymorphic polynucleotides and/or c ABL mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the c ABL mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/043898 2005-11-14 2006-11-13 Mutations and polymorphisms of c-abl Ceased WO2007058991A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73659205P 2005-11-14 2005-11-14
US60/736,592 2005-11-14

Publications (2)

Publication Number Publication Date
WO2007058991A2 WO2007058991A2 (en) 2007-05-24
WO2007058991A3 true WO2007058991A3 (en) 2007-09-07

Family

ID=37947462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043898 Ceased WO2007058991A2 (en) 2005-11-14 2006-11-13 Mutations and polymorphisms of c-abl

Country Status (1)

Country Link
WO (1) WO2007058991A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
WO2003031608A2 (en) * 2001-10-05 2003-04-17 Novartis Ag Mutated abl kinase domains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
WO2003031608A2 (en) * 2001-10-05 2003-04-17 Novartis Ag Mutated abl kinase domains

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 1418, ISSN: 0006-4971 *
CAZZANIGA GIOVANNI ET AL: "Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 548A, XP009084661, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), SHAH NEIL P ET AL: "Relapse of Chronic Phase Chronic Myeloid Leukemia (CML) on Imatinib: BCR-ABL Kinase Domain Mutations Conferring Drug Resistance Are Frequently Detectable Prior to Clinical Evidence of Relapse.", XP002436233, Database accession no. PREV200300336018 *
JABBOUR ELIAS ET AL: "Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 288A, XP009084663, ISSN: 0006-4971 *
MANLEY ET AL: "Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1754, no. 1-2, 8 September 2005 (2005-09-08), online, pages 3 - 13, XP005214189, ISSN: 1570-9639 *
VON BUBNOFF NIKOLAS ET AL: "BCR-ABL RESISTANCE SCREENING PREDICTS A LIMITED SPECTRUM OF POINT MUTATIONS TO BE ASSOCIATED WITH CLINICAL RESISTANCE TO THE ABL KINASE INHIBITOR NILOTINIB (AMN107)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 108, no. 4, 15 August 2006 (2006-08-15), pages 1328 - 1333, XP009082063, ISSN: 0006-4971 *
WILLIS STEPHANIE G ET AL: "High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy", BLOOD, vol. 106, no. 6, September 2005 (2005-09-01), pages 2128 - 2137, XP002436225, ISSN: 0006-4971 *
WULFKUHLE J ET AL: "Genomic and proteomic technologies for individualisation and improvement of cancer treatment", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 40, no. 17, November 2004 (2004-11-01), pages 2623 - 2632, XP004646472, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
WO2007058991A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
EP2896703A3 (en) Mutations of the PIK3CA gene in human cancers
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2005114190A3 (en) Methods of identifying biomarkers
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2005015155A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2007038073A3 (en) Mutations and polymorphisms of hdac11
WO2007030454A3 (en) Mutations and polymorphisms of hdac9
WO2007058992A3 (en) Mutations and polymorphisms of hdac6
WO2007109183A3 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1
MX2007008984A (en) Cancer markers and detection methods.
WO2007047998A3 (en) Mutations and polymorphisms of hdac2
WO2004113574A3 (en) Methods for disease screening
WO2007095032A3 (en) Mutations and polymorphisms of ptk2b
WO2008065544A3 (en) Genetic predictors of risk for type 2 diabetes mellitus
WO2007002217A3 (en) Mutations and polymorphisms of bcl-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837390

Country of ref document: EP

Kind code of ref document: A2